



# TELANGANA STATE POLLUTION CONTROL BOARD

Paryavarana Bhavan, A-III, Industrial Estate, Sanathnagar, Hyderabad-500 018  
Phones : 040-23887500 Fax: 040 - 23887519

**BY REGD. POST WITH ACK. DUE**

**Order No. RR-II-371/TSPCB/U-V/TF/2020- 533**

**Date:03.08.2020**

Sub : M/s Aurore Pharmaceuticals Pvt., Ltd., U-II (Earlier Mylan Laboratories, U-V), Plot No. 16/B/1, S.V.Co-operative IE, IDA, Jeedimetla, Medchal – Malkajgiri District – Water (Prevention and Control of Pollution) Amendment Act, 1988 – Air (Prevention and control of Pollution) Amendment Act, 1987 – **DIRECTIONS - Issued - Reg.**

Ref : 1. CFO order dated 13.03.2017 valid upto 31.03.2022.  
2. Inspection of the industry and its surroundings on 11.07.2020 & 13.07.2020.  
3. Notice No. 182/JDM/TSPCB/RO-MDC/2020-1107 Dated 13.07.2020.  
4. Your letter dated 16.07.2020.

\*\*\*

1. WHEREAS, you are operating the industry located at Plot No. 16/B/1, S.V.Co-operative IE, IDA, Jeedimetla, Medchal – Malkajgiri District and engaged in operation of Secondary Effluent Collection plant to treat effluents generated at M/s M/s Aurore Pharmaceuticals Pvt., Ltd., U-I (Earlier Mylan Laboratories, U-III), Plot No. 38,39, 40A, 50 & 51, Phase-IV, IDA, Jeedimetla, Medchal – Malkajgiri District which is located in the other side of Narsapur highway.
2. WHEREAS, the Board vide order dated 13.03.2017 issued CFO to the industry which is valid upto 31.03.2022 with certain conditions.
3. WHEREAS, during night patrolling on 11.07.2020, yellow colour was observed in the Jeedimetla nala at around 12:00 midnight. Tracking the yellow colour of the nala, it was observed that your industry is discharging the effluents into the nala adjacent to the industry using a hose pipe from its ETP area (about 50 meters length and 2 inch diameter). The night patrolling team has observed the following
  - a. A 2 inch hose pipe was observed to be coming out through a small gate near the transformer yard adjacent to the nala. Effluents were being clandestinely discharged from the industry into the nala through this pipe.
  - b. On entering the industry, it was observed that the other end of the pipe was connected to fixed pipeline near the inlet of the filter press below the HTDS storage tank of the industry. The effluents are supposed to be taken into filter press from the HTDS storage tank and further fed to stripper and MEE for further treatment and disposal. However, the flange connection near the filter press consisting of fixed pipe was removed and loose hose pipe was connected before the inlet of the filter press. This indicates that the industry is directly discharging the HTDS effluents into the nala instead of treatment in the MEE plant.
  - c. Hose pipe used for discharge ran across the industry from the transformer yard to the filter press area which was about 50 m. The team confiscated the hose pipe which was used for discharge of effluents. Small quantity of effluent was trapped inside the pipeline and the ends of pipe were sealed to contain the effluents inside the pipe.
  - d. Industry has provided 150 KL tank for storage of high TDS effluents. The tank was full of effluents and is overflowing. During inspection, the overflowed effluents were being cleared. The industry also has 70 KL LTDS effluent storage tank in which about 20 KL effluents were present.
  - e. Earlier, the Board issued CFO order to M/s Mylan Laboratories Unit – V, Plot No. 16/B/1, S.V.Co-op. IE, IDA, Jeedimetla, Medchal–Malkajgiri District on 01.07.2015 which was valid up to 31.03.2017. Subsequently, vide reference

DESPATCHED  
ON 4/8/2020

1<sup>st</sup> cited, the industry obtained Auto renewal of CFO of the Board stipulating conditions on 13.03.2017 which is valid up to 31.03.2022. Subsequently, on 07.06.2019, the industry has obtained name change of the industry from "M/s Mylan Laboratories Unit – V" to "M/s. Aurore Pharmaceuticals Private Limited, Unit-II" due to change of management.

f. The industry has obtained consent to manufacture the following:

S.No	Products / Line of Activity	Consented capacity as per CFO order dt.01.07.2015.
	<b>Production Unit*</b>	
1	Chloro Sulphonyl Pyrimidine	3.3 TPM
2	Bromo Pthalamide	4.1 TPM
3	Chloronitro Methyl Pyridine	0.4 TPM
4	M A 1,3 Oxathiolane Carboxylate	2.8 TPM
	<b>Secondary Effluent Treatment Plant (SETP)</b>	
5	Treatment of Industrial & domestic effluents from Unit-III, Unit-IV & Unit-V	59 KLD**

\*\* The consent order is valid for manufacture of above products and operation of SETP. However, the industry shall not carry out production at this unit without prior permission of the Board.

g. The SETP of the industry is consisting of the following units:

- The industry is segregating the effluents into High TDS and low TDS. The effluents are being collected from M/s. Aurore Pharmaceuticals Private Limited, Unit-I and treated in SETP consisting of Stripper, MEE of capacity – 80 KLD (Working capacity – 65 KLD), Agitated Thin Film Drier (ATFD) of capacity – 24 KLD.
- The industry has constructed above ground effluent collection and storage tank of capacity – 1 X 100 KL + 1 X 50 KL.
- The Low TDS effluents generated from Unit-I and Unit-II (boiler blow down, washings, domestic wastewater) along with condensate from MEE & ATFD are treated in Sequential Batch Reactors (SBRs) of capacity 60.0 KLD. ETP consists of Equalization cum neutralization tank, settler followed by SBRs and Lamella settler and RO plant of capacity – 110 KLD.
- RO permeate is being reused in cooling tower makeup/boiler feed of Unit-II and RO rejects are being treated in MEE & ATFD.

h. At present, no production of Bulk Drugs is going on in the industry and is only treating the HTDS and LTDS effluents being generated at M/s. Aurore Pharma, Unit-I (Earlier Mylan Laboratories Ltd.,) Unit-III), Plot No.38, 39, 40 A, 49 A, 50 & 51, Ph-IV, IDA, Jeedimetla, which is an API production unit. LTDS & HTDS effluents are being transferred from M/s. Aurore Pharma, Unit-I in tankers and are being treated here.

i. As per the log book, the industry has received about 22.5 KLD of effluents during 01.07.2020 to 12.07.2020 and MEE was not in operation on 12.07.2020 and hence the HTDS collection tank of the industry is full.

j. The industry is not storing the sludge generated at filter press area in a designated hazardous wastes storage shed and is dumped adjacent to the filter press area haphazardly without any dyke wall.

k. The industry has not submitted production, effluent generation and disposal, hazardous wastes generation and disposal details of both the units.

l. Samples were collected in the industry from the following locations and the analysis reports indicate the following :

Sample code	: Sample details / collection point
7234	- Sample collected from black hose pipe.
7235	- Upstream nala collected near M/s. Aurore Pharmaceuticals Private

Limited, Unit -II, (Formerly M/s. Mylan Laboratories Ltd., Unit-V), Plot No. 16/B/1, S.V.CO-op. IE, IDA, Jeedimetla, Medchal-Malkajgiri District.

7236 - Downstream nala collected near M/s. Aurore Pharmaceuticals Private Limited, Unit-II, (Formerly M/s. Mylan Laboratories Ltd., Unit-V), Plot No. 16/B/1, S.V.CO-op. IE, IDA, Jeedimetla, Medchal-Malkajgiri District.

**Sample Code: 7234**

S. No	Compounds Identified
1	Butane, 1-bromo
2	Formamide N, N dimethyl
3	DMSO
4	2-Pentane 4-hydroxy-4-methyl
5	Anisole
6	Phenol, 4-fluoro
7	Benzene methanol, alpha. alpha
8	Tributyl amine
9	2-amino 5-chloro pyridine
10	Benzoic acid, 2-hydroxy-butyl
11	4-fluoro mandelic acid
12	4, 4'- Difluoro benzhydrol
13	Phenyl methanol, 2-bromo 4, 5-dimethyl
14	2, 5-ditert-butyl aniline
15	Desmethyl citalopram
16	Escitalopram
17	Aniline, N-Ethyl-3, 5 dihydroxy

**Sample Code: 7235**

S. No	Compounds Identified
1	No compound detected

**Sample Code: 7236**

S. No	Compounds Identified	Remarks
1	Anisole	1) The compounds Sl. No. 1, 2, 3, 4, 5, 6, 7 and 8 detected in this sample are also present in Sample No. 7234 i.e., Sample collected from black hose pipe.
2	Tributyl amine	
3	Benzoic acid, 2-hydroxy butyl	
4	Benzene methanol alpha alpha	
5	Desmethyl citalopram	
6	Escitalopram	
7	Aniline, N-Ethyl-3, 5 dihydroxyl	
8	Formamide N, N dimethyl	
9	Methyl 4-amino-3-melthoxy benzoate	2) Escitalopram and Citalopram detected in this sample are drugs and they are the consented products of M/s. Aurore Pharmaceuticals Private Limited, Unit-I (formerly M/s. Mylan Laboratories Unit-III).
10	Citalopram	
11	Toluene	

**Note:** Results related to sample as received.

As per the finger printing analysis of the samples collected, the compounds: Anisole, Tributyl amine, Benzoic acid, 2-hydroxy butyl, Benzene methanol alpha alpha, Desmethyl citalopram, Escitalopram, Aniline, N-Ethyl-3, 5 dihydroxyl, Formamide N, N dimethyl identified in the sample collected from downstream of nala are matching with the sample collected from black hose pipe.

- WHEREAS, the Board on 13.07.2020 issued Show cause notice to your industry for discharging the effluents into nalla.
- WHEREAS, vide letter dated 16.07.2020, you have submitted a reply to the show cause notice issued by the Board.

6. After careful consideration of material facts of the case, the Board hereby issues following directions to your industry to comply within 15 days:
- i. The industry shall comply with all conditions stipulated in the CFO Order of the Board.
  - ii. The industry shall not carry out production at this unit without prior permission of the Board.
  - iii. The industry shall not discharge waste water outside the industry premises under any circumstances.
  - iv. The industry shall remove all the hose pipes present in the industry premises.
  - v. The industry shall transfer the chemicals /effluents/ In-process material in closed conditions to avoid smell nuisance.
  - vi. The industry shall take all necessary measures to prevent spillages from effluents storage tanks.
  - vii. The industry shall store Hazardous waste on elevated platform under a roofed shed with dyke walls & with spillage / leachage collection system.
  - viii. The industry shall send all the hazardous waste to M/s. HWMP, TSDF, Dundigal by maintaining online manifest system. The industry shall not store any hazardous waste for more than 90 days.
  - ix. The industry shall maintain good housekeeping in the premises.
  - x. The industry shall submit a BG of Rs. 08 lakhs with a validity period of one year within a week towards the compliance of the Board directions and shall also renew the BG before its expiry till further orders from the Board.
7. These directions are issued under Sec.33 (A) of Water (Prevention and Control of Pollution) Amendment Act, 1988 and under Sec. 31 (A) of Air (Prevention and Control of Pollution) Amendment Act, 1987.
8. The above mentioned directives shall be implemented by the industry, failing which legal action will be initiated against your industry under Sec.33 (A) of Water (Prevention and Control of Pollution) Amendment Act, 1988 and under Sec. 31 (A) of Air (Prevention and Control of Pollution) Amendment Act, 1987.


**Sd/-**  
**MEMBER SECRETARY**

**To**  
**M/s Aurore Pharmaceuticals Pvt., Ltd., U-II**  
**(Earlier Mylan Laboratories, U-V),**  
**Plot No. 16/B/1, S.V.Co-operative IE,**  
**IDA, Jeedimetla, Medchal**

**Copy to :**

1. The JCEE, ZO-Hyderabad for information and necessary action.
2. The EE, RO, Hyderabad for information and necessary action. The RO is directed to submit a detailed report after 15 days towards the compliance of the Board directions.
3. Concerned file.

//T.C.F.B.O//

  
**Senior Environmental Engineer (FAC)**  
**(UH - V)**